Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BuLLSEYE trial of optimized meropenem dosing in ICU patients with septic shock
NL-OMON58736Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of meropenem in sepsis and septic shock (2 arms), sponsored by Erasmus MC. Primary endpoint: 28-day mortality. Started Jan 2025; status: recruiting.
02
Drugs
meropenem
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NL-OMON58736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58736.